Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis
Authors:
Open Access
- 7 October 2021
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 14 (12) , 101238
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China Stem Cell and Translational Research (2019YFC0118100)
- National Natural Science Foundation of China (81671760, 81873910)
- National Key Research and Development Program of China
This publication has 30 references indexed in Scilit:
- Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trialBMC Cancer, 2015
- Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombusClinical Radiology, 2014
- The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in A sian patients with hepatocellular carcinoma: Final results of the START trialInternational Journal of Cancer, 2014
- Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial ChemoembolizationOncology, 2014
- Prevention of Hepatitis B Virus Infection and Liver Cancer2013
- Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical TrialThe Oncologist, 2012
- Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular CarcinomaJournal of Clinical Oncology, 2011
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEuropean Journal of Cancer, 2011
- The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2011
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003